MktsMarkets

Enliven Therapeutics, Inc.
NASDAQ: ELVNKey statistics
ELVN News
Stories mentioning ELVN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 20,687 | 21,245 | 18,225 | 21,491 | 24,895 | 20,724 | 21,258 | 18,826 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 27,823 | 34,285 | 25,096 | 28,584 | 31,693 | 26,896 | 27,068 | 24,603 |
| Operating Income (Loss) | (27,823) | (34,285) | (25,096) | (28,584) | (31,693) | (26,896) | (27,068) | (24,603) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 0.00 | 0.00 | 0.00 | (2.00) | (47.00) | 0.00 | 0.00 | (1.00) |
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 232.00 | ||||
| Net Income (Loss) | (23,627) | (29,667) | (20,148) | (25,335) | (28,544) | (23,180) | (23,156) | (19,950) |
| Earnings Per Share (Basic) | (0.38) | (0.52) | (0.32) | (0.49) | (0.57) | (0.49) | (0.48) | (0.41) |
| Earnings Per Share (Diluted) | (0.38) | (0.52) | (0.32) | (0.49) | (0.57) | (0.49) | (0.48) | (0.41) |
| Weighted Average Shares Outstanding (Basic) | 62,799 | 56,664 | 62,094 | 52,105 | 50,051 | 47,073 | 48,267 | 48,075 |
| Weighted Average Shares Outstanding (Diluted) | 62,799 | 56,664 | 62,094 | 52,105 | 50,051 | 47,073 | 48,267 | 48,075 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ELVN
Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a stock listed on the Nasdaq Stock Market under the ticker symbol ELVN. It last traded at $46.70 (Nov 17, 2026, 11:36 AM ET), down 1.9% on the day. That gives Enliven Therapeutics a market capitalisation of $3.5B.
Over the past 52 weeks ELVN has traded between $14.79 and $62.32.
For the quarter ended Mar 31, 2026 it reported a net loss of $23.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$23.6M |
| Dec 31, 2025 | — | -$29.7M |
| Sep 30, 2025 | — | -$20.1M |
| Jun 30, 2025 | — | -$25.3M |
From Enliven Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…